Rational Target Selection, Combination Design & Early Clinical Responses for TCEs
- How antigen density, tumor heterogeneity, and safety considerations guide the rational selection of TCE targets to maximize efficacy while minimizing off‑tumor toxicity
- Rationale for pairing TCEs with agents such as cytokine modulators, checkpoint inhibitors, and targeted therapies to enhance T‑cell activation, durability, and tumor penetration
- Emerging patterns in efficacy, safety, and biomarkers from first‑in‑human TCE studies, and what they reveal about translational design decisions